Table 5 |
||||||
| Distribution of A2694T PfATPase 6 polymorphism in drug sensitive groups | ||||||
| Drug | Profils | N | Strains with polymorphism PfATPase 6 A2694T | |||
| A | T | MIX | p | |||
| CQ | Resistant (IC50>100 nM) | 20 | 14 (70.0%) | 5 (25.0%) | 1 (5.0%) | 0.45 |
| Sensitive (IC50<100 nM) | 26 | 20 (76.9%) | 5 (19.2%) | 1 (3.8%) | ||
| MDAQ | Resistant (IC50 ≥ 60 nM) | 24 | 17 (69.2%) | 6 (26.9%) | 1 (3.8%) | 0.6 |
| Sensitive (IC50 < 60 nM) | 22 | 17 (80.0%) | 4 (15.0%) | 1 (5.0%) | ||
| MF | Resistant (IC50>20 nM) | 11 | 7 (63.6%) | 3 (27.3%) | 1 (9.1%) | 0.4 |
| Sensitive (IC50<20 nM) | 35 | 27 (77.1%) | 7 (20.0%) | 1 (2.9%) | ||
| DHA | Reduced susceptibility (IC50 ≥ 10 nM) | 11 | 8 (72.7%) | 3 (27.3%) | 0 (0.0%) | 0.4 |
| Sensitive (IC50<10 nM) | 35 | 26 (74.3%) | 7 (20.0%) | 2 (5.71%) | ||
Zatra et al. BMC Infectious Diseases 2012 12:307 doi:10.1186/1471-2334-12-307
